Kiniksa Pharmaceuticals International Plc Revenue Growth Rates (KNSA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Kiniksa Pharmaceuticals International Plc  (NASDAQ: KNSA)
 

KNSA's Revenue Growth by Quarter and Year

Kiniksa Pharmaceuticals International Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/KNSA/growth
https://api.csimarket.com/api/v1/companies/KNSA/fundamentals
https://api.csimarket.com/api/v1/companies/KNSA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
KNSA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 285.97
2nd Quarter June 243.60
1st Quarter March 214.27
FY 743.84

KNSAs Annual Revenue
Kiniksa Pharmaceuticals International Plc's Revenue in the fiscal year 2025 $ 677.56 millions
Kiniksa Pharmaceuticals International Plc's Revenue in the fiscal year 2024 $ 423.24 millions
Kiniksa Pharmaceuticals International Plc's Revenue in the fiscal year 2023 $ 270.26 millions
Kiniksa Pharmaceuticals International Plc's Revenue in the fiscal year 2022 $ 220.18 millions
Kiniksa Pharmaceuticals International Plc's Revenue in the fiscal year 2021 $ 38.54 millions




KNSA Revenue third quarter 2026 Y/Y Growth Comment
Kiniksa Pharmaceuticals International Plc reported Revenue rise of 58.12% year on year in the third quarter 2026, to $ 285.97 millions, this is lower than Kiniksa Pharmaceuticals International Plc's recent average Revenue surge of 121.71%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 57 other companies have achieved higher Revenue growth. While Kiniksa Pharmaceuticals International Plc' s Revenue jump of 58.12% ranks overall at the positon no. 437 in the third quarter 2026.


KNSA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 58.12 %
2nd Quarter June 55.36 %
1st Quarter March 55.5 %
FY   -

Financial Statements
Kiniksa Pharmaceuticals International Plc's third quarter 2026 Revenue $ 285.97 millions KNSA's Income Statement
Kiniksa Pharmaceuticals International Plc's third quarter 2025 Revenue $ 180.86 millions Quarterly KNSA's Income Statement


KNSA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 17.39 %
2nd Quarter June 13.69 %
1st Quarter March 6.01 %
FY (Year on Year)   -


Back to KNSA Growth rate Comparisons >> Back to KNSA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #114
Overall #437

Revenue Y/Y Growth Statistics
High Average Low
719.64 % 121.71 % -32.37 %
(Mar 31 2023)   (Jun 30 2024)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #114
Overall #437
Revenue Y/Y Growth Statistics
High Average Low
719.64 % 121.71 % -32.37 %
(Mar 31 2023)   (Jun 30 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Kiniksa Pharmaceuticals International Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
267.55 % 28.7 % -37.58 %
(Sep 30 2022)  


KNSA's III. Quarter Q/Q Revenue Comment
Kiniksa Pharmaceuticals International Plc achieved in the III. Quarter 2026 below company average Revenue jump of 17.39% quarter on quarter, to $ 285.97 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 15.34% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry only one company achieved higher sequential Revenue growth. While Kiniksa Pharmaceuticals International Plc's Revenue growth quarter on quarter, overall rank is 184.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #10
Overall #184
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #10
Overall #184
Revenue Q/Q Growth Statistics
High Average Low
267.55 % 28.7 % -37.58 %
(Sep 30 2022)  


KNSA's III. Quarter Q/Q Revenue Comment
Kiniksa Pharmaceuticals International Plc achieved in the III. Quarter 2026 below company average Revenue jump of 17.39% quarter on quarter, to $ 285.97 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 15.34% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry only one company achieved higher sequential Revenue growth. While Kiniksa Pharmaceuticals International Plc's Revenue growth quarter on quarter, overall rank is 184.


Kiniksa Pharmaceuticals International Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 945.96
Y / Y Revenue Growth (TTM) 58.19 %
Year on Year Revenue Growth Overall Ranking # 21
Seqeuential Revenue Change (TTM) 12.5 %
Seq. Revenue Growth (TTM) Overall Ranking # 210


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Kiniksa Pharmaceuticals International Plc's cumulative twelve months Revenue were $ 946 millions, company would post below average annual Revenue growth of 12.5% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Kiniksa Pharmaceuticals International Plc's Revenue growth from the 243.6% growth in Jun 30 2026.

Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 21, from total ranking in previous quarter at 118.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 9
Healthcare Sector # 5
Overall # 21

Revenue TTM Y/Y Growth Statistics
High Average Low
234.12 %
 73.61 %
20.69 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 25
S&P 500 # 210
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Kiniksa Pharmaceuticals International Plc's cumulative twelve months Revenue were $ 946 millions, company would post below average annual Revenue growth of 20.69% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Kiniksa Pharmaceuticals International Plc's Revenue growth from the 243.6% growth in Jun 30 2026.

Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 21, from total ranking in previous quarter at 118.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 9
Healthcare Sector # 5
Overall # 21

Revenue TTM Y/Y Growth Statistics
High Average Low
234.12 %
73.61 %
20.69 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 25
S&P 500 # 210




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
KNSA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions


About Kiniksa Pharmaceuticals International Plc Revenue Growth Rates (KNSA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Kiniksa Pharmaceuticals International Plc (CIK 1730430).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-119186
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Kiniksa Pharmaceuticals International Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.